Skip to main content

Uterine (Including Endometrial) Cancer Clinical Trials

Review the uterine (including endometrial) cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 266

Testing the addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Status: Active
Location: 376 locations
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Status: Active
Location: 282 locations
Using Nivolumab Alone or with Cabozantinib to Prevent Mucosal Melanoma Return after Surgery
Status: Active
Location: 132 locations
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Status: Active
Location: 117 locations
Tailoring Therapy in Post-surgical Patients with Low-risk Endometrial Cancer
Status: Active
Location: 92 locations
Induction Pembrolizumab and Chemotherapy followed by Pembrolizumab before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation with Pembrolizumab followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Status: Active
Location: 35 locations
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Status: Active
Location: 27 locations
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Status: Active
Location: 27 locations
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Status: Active
Location: 22 locations
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Status: Active
Location: 21 locations
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Status: Active
Location: 20 locations
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Status: Active
Location: 19 locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Status: Active
Location: 20 locations
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Status: Active
Location: 13 locations
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Status: Active
Location: 13 locations
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Status: Active
Location: 12 locations
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Status: Active
Location: 11 locations
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: Active
Location: 12 locations
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Status: Active
Location: 12 locations
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Status: Active
Location: 11 locations
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Status: Active
Location: 10 locations
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Status: Active
Location: 10 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Status: Active
Location: 9 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Status: Active
Location: 9 locations